Furthermore, based on the expression of CD90 on the cytomembrane [13], our team divided GA-MSCs into two subpopulations, in which the CD90high group increased the proliferation, migration and invasion of glioma cells, while the CD90low group not only regulated angiogenesis via pericyte transition but also promoted temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition [14, 15]. The gene discussed is THY1; the disease is glioma.